Vir Biotechnology (VIR) announced the appointment of Sung Lee as Executive Vice President and Chief Financial Officer, effective March 27, 2023. The appointment follows the resignation of Howard Horn, who will leave the Company after a brief transition period. Lee is an experienced CFO who brings more than 20 years of finance leadership expertise in biopharmaceutical and technology businesses to Vir. Lee most recently, served as CFO of MorphoSys AG (MOR).
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VIR:
- Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- Vir Biotechnology Announces Amended Collaboration Agreement with GSK
- Vir Biotechnology announces amended collaboration pact with GSK
- Vir Biotechnology upgraded to Equal Weight from Underweight at Morgan Stanley
- Vir Biotechnology announces retirement of CEO, Backer to succeed
